Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes
- Conditions
- Type 2 Diabetes MellitusOverweight and Obesity
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-08-18
- Last Posted Date
- 2019-05-24
- Lead Sponsor
- Zafgen, Inc.
- Target Recruit Count
- 188
- Registration Number
- NCT03254368
- Locations
- 🇳🇿
Optimal Clinical Trials, Auckland, New Zealand
🇳🇿Wellington Hospital, Wellington, New Zealand
🇦🇺Coffs Harbour GP SuperClinic, Coffs Harbour, New South Wales, Australia
An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus
- Conditions
- ObesityType 2 Diabetes
- Interventions
- Drug: ZGN-440 for Injectable SuspensionDrug: ZGN-440 Placebo for Injectable Suspension
- First Posted Date
- 2014-12-24
- Last Posted Date
- 2016-01-06
- Lead Sponsor
- Zafgen, Inc.
- Target Recruit Count
- 152
- Registration Number
- NCT02324491
- Locations
- 🇦🇺
Ipswich Research Institute, Ipswich, Queensland, Australia
🇦🇺Austin Health, Heidelberg West, Victoria, Australia
🇦🇺Royal North Shore Hospital, St. Leonards, New South Wales, Australia
Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome
- Conditions
- Prader-Willi SyndromeObesity
- Interventions
- Drug: ZGN-440 Placebo for Injectable SuspensionDrug: ZGN-440 for Injectable Suspension
- First Posted Date
- 2014-07-01
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Zafgen, Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT02179151
- Locations
- 🇺🇸
Winthrop University, Mineola, New York, United States
🇺🇸UCSD: Rady Children's Hospital, San Diego, California, United States
🇺🇸University Hospitals Case Medical Center, Cleveland, Ohio, United States
An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury
- Conditions
- ObesityCraniopharyngiomaOver-weightHypothalamic Injury
- Interventions
- Drug: ZGN-440 for injectable suspensionDrug: ZGN-440 sterile diluent
- First Posted Date
- 2014-02-14
- Last Posted Date
- 2016-07-18
- Lead Sponsor
- Zafgen, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT02063295
- Locations
- 🇺🇸
Children's Hospitals and Clinics of Minnesota, St. Paul, Minnesota, United States
🇦🇺Austin Health, Metabolic Disorders Centre, Heidelberg Heights, Victoria, Australia
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome
- Conditions
- ObesityOver-weightPrader-Willi Syndrome
- Interventions
- Drug: 1.8 mg ZGN-440 for injectable suspensionDrug: 1.2 mg ZGN-440 for injectable suspensionDrug: ZGN-440 sterile diluent
- First Posted Date
- 2013-03-27
- Last Posted Date
- 2016-07-18
- Lead Sponsor
- Zafgen, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT01818921
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects
- First Posted Date
- 2012-08-16
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- Zafgen, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT01666691
- Locations
- 🇦🇺
Q-Pharm Clinics, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
🇦🇺Linear Clinical Research Ltd, Perth, Western Australia, Australia
🇦🇺CMAX, Adelaide, South Australia, Australia
ZGN-440 (Beloranib for Subcutaneous Injection) for Treatment of Obesity
- First Posted Date
- 2012-01-10
- Last Posted Date
- 2012-07-18
- Lead Sponsor
- Zafgen, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT01507077
- Locations
- 🇦🇺
Q-Pharm Clinics, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
Pharmacokinetics, Safety, Tolerability and Efficacy of Intravenous Doses of ZGN-433 in Obese Female Volunteers
- First Posted Date
- 2011-06-14
- Last Posted Date
- 2011-12-30
- Lead Sponsor
- Zafgen, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT01372761
- Locations
- 🇦🇺
Q-Pharm Clinics, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
Safety, Tolerability and Pharmacokinetics of Multiple Doses of ZGN-433 in Obese Female Volunteers
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2012-01-11
- Lead Sponsor
- Zafgen, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT01028261
- Locations
- 🇦🇺
Nucleus Network, Heidelberg, Victoria, Australia
🇦🇺Q-Pharm Clinics, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia